This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Coronary Heart Disease (CHD) & Heart Failure (HF) Risk in Prostate Cancer Patients, Taking Casodex or Not

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: May 30, 2008
Last updated: January 30, 2013
Last verified: January 2013
A retrospective cohort study performed in the GPRD,UK. All patients with incident prostate cancer identified between 1 Jan 1999 and 31 Dec 2005 and a frequency-matched cohort of the general population will be followed- up for two outcomes; CHD including acute myocardial infarction or death from coronary heart disease and HF until Dec 31, 2006. Outcomes will be validated through requests to primary care physicians. Incidence rate´ratios of CHD and HF in the two cohorts will be calculated. In the cohort of prostate cancer the relative risk of CHD and HF associated with the use of bicalutamide compared to non-use will be estimated.

Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Pharmacoepidemiological Study on the Association Between Bicalutamide Treated Prostate Cancer and Risk of Coronary Heart Disease (CHD) and Heart Failure (HF) in the General Practice Research Database (GPRD)

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Coronary heart disease including acute myocardial infarction and death from CHD [ Time Frame: From study start 1 Jan 1999 through 31December 2006 ]
  • Heart Failure [ Time Frame: From study start 1 Jan 1999 through 31December 2006 ]

Enrollment: 5103
Study Start Date: December 2007
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Prostate cancer patients treated with bicalutamide or not
General population cohort


Ages Eligible for Study:   50 Years to 84 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
GPRD containing computerized information entered by general practitioners in the UK

Inclusion Criteria:

  • At least two years enrollment with the general practitioner

Exclusion Criteria:

  • Patients with cancer before start date of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00688532

Sponsors and Collaborators
Principal Investigator: LA García Rodríguez, MD CEIFE (Centro Español de Investigación Farmacoepidemiológica -Spanish Centre for Pharmacoepidemiologic Research) Almirante
  More Information

Responsible Party: AstraZeneca Identifier: NCT00688532     History of Changes
Other Study ID Numbers: D6874C00008
Study First Received: May 30, 2008
Last Updated: January 30, 2013

Keywords provided by AstraZeneca:
Prostate cancer
pharmacoepidemiology study

Additional relevant MeSH terms:
Prostatic Neoplasms
Heart Failure
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents processed this record on September 21, 2017